Clinical Trials Logo

Lichen Planus, Oral clinical trials

View clinical trials related to Lichen Planus, Oral.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06332365 Completed - Oral Lichen Planus Clinical Trials

Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers

salivaLichen
Start date: January 3, 2022
Phase: N/A
Study type: Interventional

Lichen planus, a chronic autoimmune mucocutaneous disorder, affects 0.5% to 2.2% of diverse populations. The treatment for oral lichen planus (OLP) includes a range of options, both topical and systemic therapies. Recent research has highlighted the potential of hyaluronic acid as a drug alternative, potentially offering effective management for OLP and alleviating the discomfort of this chronic condition. The objective was to assess the impact of topical hyaluronic acid on salivary oxidative stress markers in individuals suffering from oral lichen planus

NCT ID: NCT06204796 Completed - Clinical trials for Vitamin D Deficiency

The Role of Vitamin D in Amelioration of Oral Lichen Planus and Its Effect on Salivary IFN-γ Level

Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare between the use of vitamin D supplement in conjunction with systemic steroids versus the use of systemic steroids alone in the management of patients with symptomatic Oral Lichen Planus lesions and the comparison of salivary Interferon gamma levels in both study groups before and after treatment

NCT ID: NCT06042010 Completed - Oral Lichen Planus Clinical Trials

Oral Zinc Supplement as Adjunctive Therapy for Erosive Oral Lichen Planus

Start date: January 5, 2023
Phase: N/A
Study type: Interventional

Lichen Planus (LP) is a chronic mucocutaneous inflammatory disease and considered as T-cell mediated autoimmune disorder. Zinc is a potent antioxidant micronutrient that contributes to the proper functioning of the antioxidant defense system. In addition, this mineral protects cells against inflammation by oxidative stress, because it acts in the stabilization of cell membrane. It also maintains macrophage and neutrophil functions, natural killer cell activity, and complement activity. Matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases and have the main function of proteolytic degradation of connective tissue matrix proteins. Zinc prevents (MMP-1) activation and inhibition of the T-cell accumulation in (OLP) through inhibiting of (MMP-9). Aim of the study: To evaluate and compare the efficacy of adding oral zinc supplementation 50 mg to 0.1%Triamcinolone orabase (TA)versus 0.1%Triamcinolone orabase alone on the healing of erosive OLP.

NCT ID: NCT06033105 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Deficiency as a Risk Factor for the Development and Malignant Transformation of Oral Lichen Planus

Start date: August 1, 2023
Phase:
Study type: Observational

To investigate the role of Vitamin D (VD) deficiency as a risk factor for the development and malignant transformation of Oral lichen planus (OLP) taking into consideration sex, dietary habits, sun exposure, socioeconomic status and psychological factors.

NCT ID: NCT05951361 Completed - Clinical trials for Erosive Oral Lichen Planus

Evaluation of Diode Laser and Topical Steroid Therapy in the Treatment of Erosive Oral Lichen Planus

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

this study evaluates the effect of diode laser in treatment of oral lichen planus.

NCT ID: NCT05818618 Completed - Oral Lichen Planus Clinical Trials

Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus

Start date: March 12, 2020
Phase: N/A
Study type: Interventional

According to recent research, microRNAs (miRNAs) may function as early disease indicators and contribute to the severity of a number of precancerous and malignant oral disorders. The aim of the present study, through a double-blind randomized controlled trial design, is to analyze in the gingival crevicular fluid (GCF) as a non-invasive approach the impact of topical clobetasol on miRNAs expression in subjects affected by oral lichen planus (OLP).

NCT ID: NCT05787925 Completed - Lichen Planus Clinical Trials

Adjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus

Start date: October 20, 2022
Phase: N/A
Study type: Interventional

Oral lichen planus (OLP) is a chronic inflammatory disease affecting the skin, mucous membranes,s and rarely scalp and nails. It is a T-cell-mediated autoimmune disease. Traditional treatment for OLP is topical steroids commonly used to treat mild to moderately symptomatic lesions. Recent treatment modalities for oral lichen planus include micronutrients such as antioxidants including vitamin E that modify the immune system function. The aim of this study is to evaluate the efficacy of adjunctive oral systemic vitamin E therapy on salivary nitric oxide levels in patients with erosive oral lichen planus.

NCT ID: NCT05730855 Completed - Oral Lichen Planus Clinical Trials

Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions

Start date: November 1, 2022
Phase:
Study type: Observational

The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.

NCT ID: NCT05400057 Completed - Oral Cancer Clinical Trials

the Oncogenic Potential of Salivary miRNA-93 and miRNA-412-3P in Oral Lichen Planus Patients

Start date: January 15, 2023
Phase:
Study type: Observational

Assessment The oncogenic potential of salivary microRNA-93 and microRNA-412-3p in oral lichen planus

NCT ID: NCT05139667 Completed - Oral Lichen Planus Clinical Trials

Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus

Start date: May 20, 2019
Phase: Phase 4
Study type: Interventional

tacrolimus has been widely used as an immunosuppressant. the objective of this study was to evaluate the clinical efficacy of tacrolimus 0.1 % in muco adhesive patch compared to tacrolimus or corticosteroids in paste forms for symptomatic oral lichen planus, and to investigate the effect of topical tacrolimus or corticosteroids on the expression of caspase-3 in oral lichen planus as an early marker of apoptosis using immunohistochemically analysis